Abstract:IgA nephropathy (IgAN) is the most common primary glomerulonephritis, frequently leading to end-stage renal disease, as there is no disease-specific therapy. IgAN is diagnosed from pathological assessment of a renal biopsy specimen based on predominant or codominant IgA-containing immunodeposits, usually with complement C3 co-deposits and with variable presence of IgG and/or IgM. The IgA in these renal deposits is galactose-deficient IgA1, with less than a full complement of galactose residues on the O-glycans in the hinge region of the heavy chains. Research from the past decade led to the definition of IgAN as an autoimmune disease with a multi-hit pathogenetic process with contributing genetic and environmental components. In this process, circulating galactose-deficient IgA1 (autoantigen) is bound by antiglycan IgG or IgA (autoantibodies) to form immune complexes. Some of these circulating complexes deposit in glomeruli, and thereby activate mesangial cells and induce renal injury through cellular proliferation and overproduction of extracellular matrix components and cytokines/chemokines. Glycosylation pathways associated with production of the autoantigen and the unique characteristics of the corresponding autoantibodies in patients with IgAN have been uncovered. Complement likely plays a significant role in the formation and the nephritogenic activities of these complexes. Complement activation is mediated through the alternative and lectin pathways and probably occurs systemically on IgA1-containing circulating immune complexes as well as locally in glomeruli. Incidence of IgAN varies greatly by geographical location; the disease is rare in central Africa but accounts for up to 40% of native-kidney biopsies in eastern Asia. Some of this variation may be explained by genetically determined influences on the pathogenesis of the disease. Genome-wide association studies to date have identified several loci associated with IgAN. Some of these loci are associated with the increased prevalence of IgAN, whereas others, such as deletion of complement factor H-related genes 1 and 3, are protective against the disease. Understanding the molecular mechanisms and genetic and biochemical factors involved in formation and activities of pathogenic IgA1-containing immune complexes will enable the development of future disease-specific therapies as well as identification of non-invasive disease-specific biomarkers.

Is cardiomegaly on chest radiograph representative of true cardiomegaly: a cross-sectional observational study comparing cardiac size on chest radiograph to that on echocardiography.

Progress in Pathogenesis of Immunoglobin A Nephropathy

The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies

Familial aggregation of chronic respiratory disease: use of National Health Interview Survey data for specific hypothesis testing.

The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy

State-of-Art Therapeutics in IgA Nephropathy

The pathogenesis of IgA nephropathy and implications for treatment

Advances in the treatment of IgA nephropathy with biological agents

Effect of PNA backbone modifications on cyanine dye binding to PNA-DNA duplexes investigated by optical spectroscopy and molecular dynamics simulations.

Relationship between BMI, physical fitness, and motor skills in youth with mild intellectual disabilities

New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies

IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment

The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy

Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment

Drugs in Development to Treat IgA Nephropathy

Decrypting the Pathological Pathways in IgA Nephropathy

[Value of rectosigmoidoscopy in the secondary prevention of carcinoma of the colon and rectum. Results of a study of ours carried out in elderly patients].

Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune Disease

The Role of Immune Modulation in Pathogenesis of IgA Nephropathy

Biomarkers and targeted new therapies for IgA nephropathy

Pathogenic Immunoglobulin A-Producing Cells in Immunoglobulin A Nephropathy